DEA Rescheduling Hearing Begins June 29: What Schedule III Means for Cannabis

The most consequential federal cannabis proceeding in decades kicks off on June 29, 2026, when the Drug Enforcement Administration convenes an expedited administrative hearing at its Arlington, Virginia facility. At stake is whether all forms of marijuana should be moved from Schedule I — the most restrictive category, shared with heroin and LSD — to Schedule III of the Controlled Substances Act, joining substances like ketamine and anabolic steroids.

For an industry that has operated in a legal gray zone for over a decade, the hearing represents the closest the federal government has ever come to aligning policy with the reality on the ground: 24 states with legal adult-use programs, 40 with medical frameworks, and a domestic market valued in the tens of billions.

How We Got Here

The road to this hearing has been anything but straightforward. The process gained sudden momentum on December 18, 2025, when President Trump signed an Executive Order on Increasing Medical Marijuana and Cannabidiol Research, directing Attorney General Pam Bondi to expedite the rescheduling process.

On April 21, 2026, the Justice Department and DEA took a landmark interim step, issuing a final order that immediately placed two categories of marijuana into Schedule III: FDA-approved products containing marijuana and marijuana products sold under a qualifying state-issued medical license. That order took effect the same day, providing instant relief to a subset of the industry while the broader question remained open.

The April order, however, left unlicensed marijuana crops and bulk marijuana in Schedule I. It also did nothing for the adult-use market. The June 29 hearing exists to determine whether the remaining marijuana products should follow.

The Hearing: Logistics and Structure

The proceeding will run from June 29 through no later than July 15, 2026, at the DEA Hearing Facility at 700 Army Navy Drive in Arlington. In a nod to the national holiday, the hearing will recess on July 3 and resume on July 6.

The format is a formal administrative hearing under the Controlled Substances Act's rulemaking procedures. An administrative law judge will preside, hearing testimony from government witnesses, industry stakeholders, medical researchers, and opponents. The participation deadline for interested parties passed on May 28, 2026, meaning the roster of witnesses and exhibitors is already locked in.

This is not a congressional hearing or a public comment period — it is a quasi-judicial proceeding with sworn testimony, cross-examination, and evidentiary standards. The administrative law judge will issue a recommended decision, which the DEA Administrator can accept, reject, or modify.

What Schedule III Actually Means

The distinction between Schedule I and Schedule III is not merely symbolic. Under current Schedule I classification, marijuana is officially defined as having "no currently accepted medical use" and a "high potential for abuse." Schedule III substances, by contrast, are recognized as having accepted medical applications and a lower abuse potential.

The practical consequences of rescheduling touch nearly every aspect of the cannabis ecosystem.

Tax Relief Under Section 280E

The most immediate financial impact involves Internal Revenue Code Section 280E, which prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. Cannabis companies currently face effective tax rates of 70% or higher because they cannot deduct payroll, rent, marketing, or interest expenses.

Moving to Schedule III would eliminate the 280E restriction for medical cannabis operators. Industry analysts at Viridian Capital Advisors estimate the twelve largest multi-state operators alone would save a combined $700 million or more annually. The aggregate industry savings could reach $2.3 billion per year.

However, the relief is not blanket. Under the April interim order, only state-licensed medical marijuana qualifies for Schedule III treatment. Adult-use cannabis remains Schedule I and subject to 280E. Companies operating in mixed medical and recreational markets will need careful recordkeeping to separate deductible and non-deductible activities.

Research Expansion

Schedule I classification has been the single greatest barrier to clinical cannabis research in the United States. Researchers need a DEA license to work with Schedule I substances, and historically the only legal source of research-grade marijuana was the University of Mississippi's federally contracted grow facility.

Schedule III classification would dramatically lower these barriers. Researchers could more easily obtain DEA registration, source cannabis from a wider range of suppliers, and design studies without the extraordinary administrative burden that has suppressed American cannabis research for decades.

Banking and Financial Services

While rescheduling alone does not resolve every banking challenge — marijuana would still not be fully legal at the federal level — Schedule III status reduces the perceived risk for financial institutions. Banks and credit unions that have avoided cannabis clients due to anti-money laundering concerns may find Schedule III provides sufficient legal cover to offer basic services like business accounts, loans, and payment processing.

The Opposition

Not everyone welcomes rescheduling. A coalition of organizations, including the anti-legalization group Smart Approaches to Marijuana, has filed lawsuits attempting to block the process. Their arguments range from procedural challenges — questioning whether the expedited timeline violates due process — to substantive claims that marijuana does not meet the medical and scientific criteria for Schedule III.

Some public health advocates have expressed concern that rescheduling sends a normalization signal without adequate safeguards around youth access, impaired driving, and product potency. These concerns are likely to feature prominently in the hearing testimony.

What Happens After the Hearing

The administrative law judge's recommended decision is not the final word. The DEA Administrator reviews the recommendation and issues a final rule, which is then published in the Federal Register and subject to a comment period. Legal challenges are virtually certain regardless of the outcome.

Optimistic timelines suggest a final rule could be in place by late 2026 or early 2027, but the formal rulemaking process and inevitable litigation could extend the timeline considerably. Industry observers recall that the previous rescheduling attempt, initiated under the Biden administration in 2023, was derailed by procedural delays and legal challenges before the Trump executive order restarted the process on an expedited track.

What This Means for Patients and Consumers

For medical cannabis patients, the hearing's outcome could determine whether their medicine is treated with the same regulatory legitimacy as other prescribed substances. Schedule III status would not make marijuana available at CVS or Walgreens overnight, but it would remove the federal stigma that has complicated insurance coverage, employment protections, and physician willingness to recommend cannabis.

For adult-use consumers, the immediate impact is less direct. Even full rescheduling to Schedule III does not legalize recreational marijuana at the federal level. State-by-state legalization would continue to be the operative framework for adult-use markets. However, the symbolic and political weight of removing marijuana from Schedule I cannot be overstated — it would represent the federal government's formal acknowledgment that decades of the most restrictive classification were scientifically unjustified.

The Bottom Line

The June 29 hearing is not the end of the rescheduling story, but it is the most significant procedural milestone in the history of federal cannabis reform. The testimony presented over those two weeks will form the evidentiary record on which the DEA's final decision rests. For an industry and a patient community that has waited decades for this moment, the countdown is finally measured in days rather than years.